Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

clinical trial

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT02446405

P6099clinical trial phasephase III clinical trialQ42824827
P767contributor to the creative work or subjectCancer Trials IrelandQ30268773
P17countryCanadaQ16
IrelandQ27
United States of AmericaQ30
AustraliaQ408
United KingdomQ145
New ZealandQ664
P582end time2020-09-01
P921main subjectmetastatic prostate carcinomaQ55779807
P2899minimum age18
P1132number of participants1125
P6153research siteUniversity of TorontoQ180865
Dana–Farber Cancer InstituteQ1159198
Griffith UniversityQ1202292
Christchurch HospitalQ1278898
Royal Hobart HospitalQ2171042
Auckland City HospitalQ4819504
Cross Cancer InstituteQ5188247
Ottawa UniversityQ7109265
Royal Adelaide HospitalQ7373582
Sir Charles Gairdner HospitalQ7526207
Townsville HospitalQ7830280
Waikato HospitalQ7959998
Saint John Regional HospitalQ14875635
CancerCare ManitobaQ30282110
Chris O’Brien LifehouseQ30282252
Thunder Bay Regional Research InstituteQ30296451
Princess Alexandra HospitalQ50573098
P1813short nameENZAMET
P580start time2014-03-01
P8363study typeinterventional studyQ78089383
P1476titleRandomised Phase 3 Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET

Search more.